| P50 | author | Akseli Hemminki | Q26920981 |
| | Maiju Merisalo-Soikkeli | Q64382148 |
| | Anna Kanerva | Q64398934 |
| | Markus Vähä-Koskela | Q42305481 |
| | Susanna Grönberg-Vähä-Koskela | Q42305494 |
| P2093 | author name string | Siri Tähtinen | |
| | Suvi Parviainen | |
| | Saija Kaikkonen | |
| P2860 | cites work | TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu | Q21131200 |
| | CD28/B7 system of T cell costimulation | Q24313544 |
| | Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells | Q24530100 |
| | Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma | Q24548019 |
| | Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy | Q24596055 |
| | Trial Watch | Q24618653 |
| | Exploiting a natural conformational switch to engineer an interleukin-2 'superkine' | Q24632192 |
| | T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Q24632975 |
| | Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens | Q24644442 |
| | Innate and adaptive immune cells in the tumor microenvironment | Q27008342 |
| | Tumor-induced perturbations of cytokines and immune cell networks | Q27021807 |
| | CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients | Q27692628 |
| | Macrophage plasticity and polarization: in vivo veritas | Q29547620 |
| | Microenvironmental regulation of tumor progression and metastasis | Q29615504 |
| | Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 |
| | Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans | Q30571240 |
| | TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility | Q33239894 |
| | A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma | Q33606083 |
| | Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells | Q33990255 |
| | Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors | Q34052580 |
| | Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients | Q34116267 |
| | Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. | Q51989826 |
| | Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses | Q52005024 |
| | Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. | Q54432520 |
| | Prognostic Value of Intratumoral Interferon Gamma Messenger RNA Expression in Invasive Cervical Carcinomas | Q56966580 |
| | Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer-Specific Immune Responses and Their Correlation to Prognosis | Q57270774 |
| | Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor | Q72098225 |
| | Interferons alpha and beta as immune regulators--a new look | Q34289965 |
| | IL-2: the first effective immunotherapy for human cancer. | Q34423519 |
| | Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. | Q34531618 |
| | A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 |
| | IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients | Q34657691 |
| | Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis | Q35056748 |
| | GM-CSF-secreting melanoma vaccines | Q35146599 |
| | Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance | Q35690984 |
| | The colony-stimulating factors and cancer | Q35936937 |
| | Trial Watch: Immunostimulatory cytokines | Q36057492 |
| | Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. | Q36432026 |
| | Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors | Q36845800 |
| | Cytokines in cancer immunotherapy | Q37148152 |
| | Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants | Q37519025 |
| | The secret ally: immunostimulation by anticancer drugs | Q37981038 |
| | CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. | Q38011892 |
| | Accumulation in tumor tissue of adoptively transferred T cells: A comparison between intravenous and intraperitoneal injection | Q40280081 |
| | Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells | Q40497311 |
| | IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. | Q40618350 |
| | Radiotherapy effects on anti-tumor immunity: implications for cancer treatment | Q40914349 |
| | Implications for immunosurveillance of altered HLA class I phenotypes in human tumours | Q41370602 |
| | Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor | Q41730063 |
| | IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. | Q42097481 |
| | CARs on track in the clinic | Q42649114 |
| | Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion | Q42809739 |
| | Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? | Q43960023 |
| | Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators | Q44021835 |
| | Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity | Q44890780 |
| | Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins | Q45171571 |
| | Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. | Q46014872 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0131242 | |
| P577 | publication date | 2015-06-24 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors | |
| P478 | volume | 10 | |